Frontiers in Pharmacology | Pharmacoepidemiology

Original Research

Published on 22 Nov 2023

Dose-response association of metformin use and risk of age-related macular degeneration among patients with type 2 diabetes mellitus: a population-based study

in Pharmacoepidemiology

Kuang-Hua Huang
Ya-Lan Chang
Chiachi Bonnie Lee
Shuo-Yan Gau
Tung-Han Tsai
Ning-Jen Chung
Chien-Ying Lee

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1275095

3,273 views
6 citations

Original Research

Published on 21 Nov 2023

Adverse events in patients with advanced urothelial carcinoma treated with erdafitinib: a retrospective pharmacovigilance study

in Pharmacoepidemiology

Tengfei Yuan
Faping Li
Yuchuan Hou
Hui Guo

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1266890

4,476 views
16 citations

Original Research

Published on 16 Nov 2023

Associated adverse health outcomes of polypharmacy and potentially inappropriate medications in community-dwelling older adults with diabetes

in Pharmacoepidemiology

Lvliang Lu
Shuang Wang
Jiaqi Chen
Yujie Yang
Kai Wang
Jing Zheng
Pi Guo
Yunpeng Cai
Qingying Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1284287

4,562 views
8 citations

Original Research

Published on 16 Nov 2023

Antidepressants use during pregnancy and child psychomotor, cognitive and language development at 2 years of age—Results from the 3D Cohort Study

in Pharmacoepidemiology

Noémie Tanguay
Nadia Abdelouahab
Marie-Noelle Simard
Jean R. Séguin
Isabelle Marc
Catherine M. Herba
Andrea A. N. MacLeod
Yohann Courtemanche
William D. Fraser
Gina Muckle

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1252251

5,192 views
6 citations

Original Research

Published on 14 Nov 2023

Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration’s adverse event reporting system (FAERS)

in Pharmacoepidemiology

Victor Pera
Guy G. Brusselle
Sebastian Riemann
Jan A. Kors
Erik M. Van Mulligen
Rowan Parry
Marcel de Wilde
Peter R. Rijnbeek
Katia M. C. Verhamme

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1276340

9,406 views
18 citations

Original Research

Published on 10 Nov 2023

Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database

in Pharmacoepidemiology

Wensheng Liu
Qiong Du
Zihan Guo
Xuan Ye
Jiyong Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1283247

9,734 views
27 citations

Original Research

Published on 09 Nov 2023

The influence of general practitioner and patient sex on the treatment of major depression

in Pharmacoepidemiology

Elisabeth Jufresa-Blanch
Neus Carrilero
Anna García-Altés

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1274774

3,033 views
2 citations

Original Research

Published on 09 Nov 2023

Gender differences in spontaneous adverse event reports associated with zolpidem in South Korea, 2015–2019

in Pharmacoepidemiology

Kyung-In Joung

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1256245

3,981 views
4 citations

Original Research

Published on 07 Nov 2023

Antihypertensive medications and risk of colorectal cancer in British Columbia

in Pharmacoepidemiology

Jia Qi
Parveen Bhatti
John J. Spinelli
Rachel A. Murphy

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1301423

2,427 views
3 citations

Original Research

Published on 06 Nov 2023

Sodium-glucose cotransporter–2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis

in Pharmacoepidemiology

Annamaria Mascolo
Concetta Rafaniello
Gabriella di Mauro
Donatella Ruggiero
Maria Rosaria Campitiello
Maria Donniacuo
Pasquale Maria Berrino
Francesco Rossi
Giuseppe Paolisso
Annalisa Capuano

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1245642

4,046 views
5 citations

Brief Research Report

Published on 03 Nov 2023

Statutory health insurance-covered pre-exposure prophylaxis in Germany: changing trends in nationwide tenofovir disoproxil/emtricitabine prescriptions during the COVID-19 pandemic

in Pharmacoepidemiology

Henrieke Prins
Achim Dörre
Daniel Schmidt

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1241310

5,077 views
4 citations

Original Research

Published on 01 Nov 2023

Associations between COVID-19 outcomes and asthmatic patients with inhaled corticosteroid

in Pharmacoepidemiology

Su-Boon Yong
Shuo-Yan Gau
Chia-Jung Li
Chih-Wei Tseng
Shiow-Ing Wang
James Cheng-Chung Wei

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1204297

3,764 views
12 citations

Original Research

Published on 31 Oct 2023

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system

in Pharmacoepidemiology

Yankun Liang
Lin Ma
Yuting Wang
Jingping Zheng
Ling Su
Jun Lyu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1253799

6,286 views
12 citations

Original Research

Published on 30 Oct 2023

Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study

in Pharmacoepidemiology

Yun-Kyoung Song
Gaeun Lee
Jinseub Hwang
Ji-Won Kim
Jin-Won Kwon

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1165711

6,016 views
9 citations

Original Research

Published on 30 Oct 2023

Do disease-modifying antirheumatic drugs and non-steroidal anti-inflammatory drugs increase the burden on ankylosing spondylitis patients with mild-moderate COVID-19? evidence from a retrospective cohort study

in Pharmacoepidemiology

Yan Li
Zhengyuan Hu
Yufei Guo
Zheng Zhao
Kunpeng Li
Xiuru Wang
Jie Zhang
Dongfeng Liang
Jianglin Zhang
Xiaoyue Hu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1266915

2,749 views
3 citations

Original Research

Published on 26 Oct 2023

Big data- and machine learning-based analysis of a global pharmacovigilance database enables the discovery of sex-specific differences in the safety profile of dual IL4/IL13 blockade

in Pharmacoepidemiology

Kassem Sharif
Mahmud Omar
Adi Lahat
Yonatan Shneor Patt
Howard Amital
Ghanem Zoabi
Nicola Luigi Bragazzi
Abdulla Watad

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1271309

4,202 views
3 citations

Original Research

Published on 26 Oct 2023

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?

in Pharmacoepidemiology

Zhiwei Cui
Feiyan Cheng
Lihui Wang
Fan Zou
Rumeng Pan
Yuhan Tian
Xiyuan Zhang
Jing She
Yidan Zhang
Xinyuan Yang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1259908

7,929 views
40 citations

Systematic Review

Published on 24 Oct 2023

Comparison of biologics and small-molecule drugs in axial spondyloarthritis: a systematic review and network meta-analysis

in Pharmacoepidemiology

Erye Zhou
Jian Wu
Keqin Zeng
Mingjun Wang
Yufeng Yin

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1226528

6,086 views
6 citations

Original Research

Published on 20 Oct 2023

Neurocognitive impairment in females with breast cancer treated with endocrine therapy and CDK4/6 inhibitors: a pharmacovigilance study using the World Health Organization’s database

in Pharmacoepidemiology

Rachel Prevost
Basile Chretien
Elise-Marie Minoc
Charles Dolladille
Angélique Da-Silva
Ahmad Nehme
Florence Joly
Véronique Lelong-Boulouard
Etienne Bastien

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1278682

6,253 views
6 citations

Opinion

Published on 11 Oct 2023

Nutrivigilance: the road less traveled

in Pharmacoepidemiology

Vijay Ronit Luthra
Hale Z. Toklu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1274810

5,907 views
7 citations

Policy and Practice Reviews

Published on 11 Oct 2023

A blueprint for success in real-world evidence: “glocal” approach to building capabilities and generating impactful evidence

in Pharmacoepidemiology

Kristoffer Larsen
Ryan N. Walton
Mohamed Elsayed
Andrey Ipatov
Faye Townsend-Holyoake
Sebastian F. A. Axelsson
Nacho Quinones
Rudiger Papsch
Jennifer Givens
Alexander Bedenkov

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1233617

9,590 views
2 citations

Brief Research Report

Published on 10 Oct 2023

A retrospective real-world study of early short-course remdesivir in non-hospitalized COVID-19 patients at high risk for progression: low rate of hospitalization or death, regardless of immunocompetence status

in Pharmacoepidemiology

José Manuel Ramos-Rincón
Héctor Pinargote-Celorio
Jara Llenas-García
Oscar Moreno-Pérez
Inmaculada González-Cuello
Pilar Gonzalez-de-la-Aleja
Belén Martínez-López
Sergio Reus
María García-López
Juan Carlos Rodríguez

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1218650

3,268 views
8 citations

Original Research

Published on 09 Oct 2023

Impact of domiciliary administration of NSAIDs on COVID-19 hospital outcomes: an unCoVer analysis

in Pharmacoepidemiology

Elena Salvador
Cristina Mazzi
Nicoletta De Santis
Giulia Bertoli
Antonija Jonjić
Miran Coklo
Marek Majdan
José L. Peñalvo
Dora Buonfrate

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1252800

1,893 views

Original Research

Published on 02 Oct 2023

Infections associated with clozapine: a pharmacovigilance study using VigiBase®

in Pharmacoepidemiology

Basile Chrétien
Perrine Brazo
Angélique Da Silva
Marion Sassier
Charles Dolladille
Véronique Lelong-Boulouard
Joachim Alexandre
Sophie Fedrizzi

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1260915

5,969 views
7 citations

599 articles

articles

Dose-response association of metformin use and risk of age-related macular degeneration among patients with type 2 diabetes mellitus: a population-based study

Adverse events in patients with advanced urothelial carcinoma treated with erdafitinib: a retrospective pharmacovigilance study

Associated adverse health outcomes of polypharmacy and potentially inappropriate medications in community-dwelling older adults with diabetes

Antidepressants use during pregnancy and child psychomotor, cognitive and language development at 2 years of age—Results from the 3D Cohort Study

Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration’s adverse event reporting system (FAERS)

Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database

The influence of general practitioner and patient sex on the treatment of major depression

Gender differences in spontaneous adverse event reports associated with zolpidem in South Korea, 2015–2019

Antihypertensive medications and risk of colorectal cancer in British Columbia

Sodium-glucose cotransporter–2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis

Statutory health insurance-covered pre-exposure prophylaxis in Germany: changing trends in nationwide tenofovir disoproxil/emtricitabine prescriptions during the COVID-19 pandemic

Associations between COVID-19 outcomes and asthmatic patients with inhaled corticosteroid

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system

Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study

Do disease-modifying antirheumatic drugs and non-steroidal anti-inflammatory drugs increase the burden on ankylosing spondylitis patients with mild-moderate COVID-19? evidence from a retrospective cohort study

Big data- and machine learning-based analysis of a global pharmacovigilance database enables the discovery of sex-specific differences in the safety profile of dual IL4/IL13 blockade

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?

Comparison of biologics and small-molecule drugs in axial spondyloarthritis: a systematic review and network meta-analysis

Neurocognitive impairment in females with breast cancer treated with endocrine therapy and CDK4/6 inhibitors: a pharmacovigilance study using the World Health Organization’s database

Nutrivigilance: the road less traveled

A blueprint for success in real-world evidence: “glocal” approach to building capabilities and generating impactful evidence

A retrospective real-world study of early short-course remdesivir in non-hospitalized COVID-19 patients at high risk for progression: low rate of hospitalization or death, regardless of immunocompetence status

Impact of domiciliary administration of NSAIDs on COVID-19 hospital outcomes: an unCoVer analysis

Infections associated with clozapine: a pharmacovigilance study using VigiBase®